🇬🇧 The Synergy of Data-Driven Health and Data-Driven Informational Peptide Drug Discovery in Dealing with Data-Driven Health and a Universal N=1 Healthcare » Luxembourg Institute of Health
Home » Events » 🇬🇧 The Synergy of Data-Driven Health and Data-Driven Informational Peptide Drug Discovery in Dealing with Data-Driven Health and a Universal N=1 Healthcare

🇬🇧 The Synergy of Data-Driven Health and Data-Driven Informational Peptide Drug Discovery in Dealing with Data-Driven Health and a Universal N=1 Healthcare

12/05/2025 09:00 to 09:45

Data-driven health employs a genome and longitudinal phenome analysis of each of many individuals to decipher their individual biological complexities and turn these insights into actionable possibilities to optimize wellness and healthy aging, to avoid disease, and to gain causal insights into wellness and disease.

Two major factors influence each individual’s health trajectory—their behavior and their environment—and these influences are followed through longitudinal phenomic measurements. The actionable possibilities, so derived, will be processed through a knowledge graph to provide proper educational metadata for a transformer.

Statistical analyses and machine learning analyses of individual genome and phenome data also lead to the discovery of many new possible drug candidates for wellness and prevention. For these targets, we plan to employ peptide drug discovery techniques that will utilize large-scale DNA synthesis to generate millions to billions of peptide genes and then use the tools of cell and molecular biology to interrogate these drugs individually through phenotypic and targeted selection procedures.

This approach will also map the peptide drugs’ individual transcriptional activities by single-cell analyses in 100 or more human cell lines and organelles and process each through a knowledge graph to generate the metadata used to instruct a transformer to model the optimization of drug use in individuals. These drugs will relate both to the optimization of wellness and aging and early detection of disease transitions and their reversal—as relates to both individual behaviors and environmental influences.

I will discuss these two AI-driven approaches to healthcare—data-driven health and informational peptide drug discovery—and their AI-driven synergies in moving to an N=1 healthcare.

Following Prof. Hood’s talk, there will be a Q&A session.

Speaker

Prof. Leroy
Hood, MD, PhD

CEO, Phenome Health


Chief Innovation Officer,
Distinguished Professor,
Buck Institute for Research on Aging


Professor and Co-founder,
Institute for Systems Biology


Host
Ulf
Nehrbass

CEO, Luxembourg Institute of Health


LOCATION

LIH Edison
Curie/Pasteur room (3rd floor)
1B rue Thomas Edison
L-1445 Strassen, Lux

WEBINAR VIA WEBEX

Event number: 2731 878 7164
Event password: W4SrJcjkh64

REGISTRATION

Please register by sending an email to: florence.henry@lih.lu

Share

DATA PRIVACY

Read more about the “Data Protection Notice: processing of personal data in the scope of events’ management”.

Forthcoming events